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Summary.-In 132 consecutive patients with carcinoma of various organs, a higher
serum immunoreactive calcitonin (ICT) concentration (median level 50 pg/ml) was
found than in 68 normal subjects (median level 20 pg/ml). The incidence of hyper-
calcitoninaemia was 40%o. All 9 patients with primary liver-cell carcinoma were
hypercalcitoninaemic. On the other hand, none of the 7 patients with a carcinoma of
the breast had raised ICT levels. In bronchogenic cancer a relationship between
ICT and cell type was found, with a predominance of high ICT in patients with oat-
cell and other undifferentiated types, whereas in squamous-cell carcinomas and
adenocarcinomas of the lung hypercalcitoninaemia was relatively rare.
When we divided all our patients according to differentiation of the tumour cell, it
was found that the lower the degree of differentiation, the higher the ICT concen-
tration, whereas opposite results were observed for CEA.
When ICT and CEA were estimated concurrently, we found at least one marker
increased in70%o of our patients.
Our results demonstrate that patients with metastases in the liver have more
frequently an increased ICT. In addition, we conclude that lifespan can be expected
to be lower in patients with high ICT levels. In a longitudinal study of 46 patients,
there was a positive correlation between change in serum ICT and tumour mass.
IN 1971, Milhaud et al. described 2
patients with a carcinoid tumour and in-
creased serum immunoreactive calcitonin
(ICT) concentrations. Since then several
publications have appeared concerning
ectopic ICT production (Kaplan et al.,
1972; Silva et al., 1973; Whitelaw &
Cohen, 1973). At first, patients with bone
metastases were reported to be hyper-
calcitoninaemic (HYCAL) (Coombes et
al., 1975; Milhaud et al., 1976) though
Silva et al. (1976) found increased serum
ICT concentrations in 56% of their
patients with, and in 70%0 without bone
metastases.
Coombes et al. (1975) showed that
HYCAL could have prognostic value.
Dambacher et al. (1977) suggested that
it was found exclusively in patients who
had already developed metastases. In
patients with bronchogenic carcinoma, the
finding of HYCAL could predict the
histological type, as patients with oat-cell
carcinoma more frequently had increased
serum ICT concentrations than those with
squamous-cell carcinoma (McKenzie et al.,
1977; Silva et al., 1976; Tashjian, 1976).
Because of all these qualities, Williams
(1976) predicted that ICT could be an
important "marker", especially in bron-
chogenic carcinoma.
That HYCAL in tumour patients does
not always imply ectopic ICT production
has been shown by Silva et al. (1976). In a
patient with an adenocarcinoma of the
lung, they demonstrated strongly in-
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creased ICT secretion from the thyroid
gland. During a period of 2 years, patients
with malignant tumours were subjected
to an investigation to test whether a rela-
tionship exists between the level of
ICT and the incidence of HYCAL on the
one hand and the primary organic site
of the tumour, cell type, grade of differen-
tiation ofthe cell and extension oftumour
mass on the other.
In addition to ICT, CEA concentration
in the serum was measured in the first 79
patients, to establish whether the respec-
tive elevations were overlapping or com-
plementary.
METHODS
Patients.-Only patients with a histo-
logically proven malignancy were included in
this study, an exception being made for those
with bronchogenic carcinoma. These were
included when cytologically positive sputum
was demonstrated on 3 occasions. Only
normocalcaemic patients with a normal renal
function were studied.
For evaluation of changes of tumour mass,
volumetric criteria were used, together with
biochemical data clearly related to tumour
extension, such as changes in serum alkaline
phosphatase and lactic dehydrogenase levels
in the case of liver metastases. Volume was
assessed using data from physical, radio-
isotope and X-ray examination. When a
tumour could be palpated the product of the
largest diameter and its perpendicular
measurement were chosen. For measuring
localized X-ray and scintigraphic abnor-
malities the same technique was used. The
number of "hot spots" in the bone scan was
counted.
The differentiation of the tumour was
classified as well differentiated, moderately
differentiated, poorly differentiated or un-
differentiated.
The bronchogenic carcinomas were sub-
divided histologically according to the classi-
fication ofSitsen (1959).
The existence of metastases in the liver
was based on scintigraphic, laparoscopic and
biopsy criteria.
In 46 patients a follow-up was done during
a period of 60 + 20 days. The patients were
reassessed after this interval, during which
they were treated by surgery (18), radiation
(10), cytostatic drugs (9) or left untreated (9).
Progressive disease was defined as either
an increase in measurable tumour size of
more than 25%, the appearance of meta-
stases at new sites, or an increase in the
number ofmetastases on scintigraphy ofbone
and liver or on chest X-ray. Regression was
considered to exist in all cases where opera-
tion had remaved the total or subtotal
tumour mass, and in those patients in whom
the other treatment methods gave a reduction
in size of more than 25%.
The actuarial survival was calculated
according to the method of Berkson & Gage
(1950).
Calcitonin was determined by the radio-
immunoassay system described by Hackeng
et at. (1970) with antiserum G5 instead of
antiserum 9654 (Lamberts et al., 1980).
Detection limit of the assay is 20 pg/ml. The
normal value is <60 pg/ml. Carcino-embry-
onic antigen (CEA) was measured by the
technique of Persyn & Korsten (1976), which
is a modified direct radio-immunoassay. The
normal level is <6 ng/ml for non-smokers
and < 10 ng/ml for smokers.
Statistics.-As the investigated popula-
tion(s) are not normally distributed, the
median and upper limit are displayed and
used. Wilcoxon's test for two samples was
used to test for significance. Throughout this
paper, the word "significant" indicates a
probability at the 0 05 level or less.
RESULTS
A total of 135 patients was studied:
74 men (average age 66 years) and 61
women (average age 71). The median ICT
levels, interquartile ranges and the per-
centages with hypercalcitoninaemia (HY-
CAL), grouped according to the site of
the primary cancer, are summarized in
Table I.
Table II shows the same data for
patients with bronchogenic carcinoma,
subdivided according to cell type. Table I
shows that 40% of all patients had high
serum ICT concentrations. All 9 patients
with a hepatoma had increased serum
ICT concentrations. Division of broncho-
genic tumours according to cell type shows
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TABLE I.-Median ICT concentration (their interquartile ranges and % ofpatients with
hypercalcitoninaemia, HYCAL) in 132 cases with a malignancy, grouped according to
theprimary site
Inter-
Median quartile
ICT range °
Cancer No. (pg/ml) (pg/ml) P* HYCAL
Bronchogenic 53 50 30-260 < 0-001 40
Large bowel 29 40 30-150 < 0-001 37
Stomach 23 50 30-210 < 0-001 39
Liver 9 290 190-710 < 0-001 100
Breast 7 35 0
Kidney 5 80 60
Oesophagus 3 20 (0)
Ovary 3 130 (67)
Pancreas 3 70 (33)
Total 135 50 30-240 40
Normal subjects 68 20 20-30 0
* Significance of comparison with normal subjects.
TABLE II.-Median ICT concentrations and percentages of hypercalcitoninaemia
in 53 patients with a bronchogenic carcinoma
Cell type
Squamous
Adeno
Undifferentiated
Oat cell
Normal subjects
No.
24
5
14
10
68
Median
ICT
(pg/mi)
40
40
100
120
20
Inter-
quartile
range %
(pg/ml) P* HYCAL
30-120 < 0 005 25
0
60-102 < 0.001 71
50-260 < 0-001 70
60 0
* Significance of comparison with normal subjects.
that both the median level and the inci-
dence of HYCAL were most obviously
increased in patients with oat-cell and
undifferentiated carcinomas, whereas
patients with a squamous-cell tumour had
an unexpected low incidence and median
level.
It was remarkable that none of the 7
patients with a carcinoma ofthe mammary
glandhad HYCAL. As agroupthe patients
with bronchogenic, large-bowel, stomach
orliver carcinoma hadsignificant increased
serum ICT concentrations. Fig. 1 shows
that changes in serum ICT follow changes
in tumour volume. In patients with regres-
sion in size the median ICT concentration
declined from 180 pg/ml to 70 pg/ml
(P < 0.005). This fall was especially marked
when the initial ICT was very high. Two
of these 17 patients had an increase, in
spite of regression of tumour volume.
The group with unchanged volume had
no significant change in their serum ICT.
The 23 patients with an increasing tumour
volume demonstrated a rise in their
median serum ICT from 220 pg/ml to
290 pg/ml (P < 0.05), but 3 patients in this
group had a fall of this concentration.
In Table III the patients are grouped
according to the affected organ, and sub-
sequently subdivided in patients with
and without liver metastases. In all groups
(i.e. bronchogenic, gastric and large-bowel
carcinoma) those with liver metastases
had significantly higher serum ICT con-
centrations.
The median ICT concentration in
patients with or without bone metastases
did not differ significantly (within each
tumour group).
Table IV demonstrates the relationship
between morphological differentiation of
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FIa. 1.-Relationship between change in tumour volume and change in ICT concentration during
prospective longitudinal study in 46 patients.
TABLE III.-Median ICT concentrations
in patients without and with liver or bone
metastases, grouped according to the
primary site.
Primary Meta-
tumour stases
in Liver
Median
ICT
No. (pg/mi) p
TABLE IV.-Median ICT (pg/ml) and
CEA (ng/ml) in 3 primary localizations
grouped according to the degree of differ-
entiation ofthe tumour cell.
Degree of differentiation
, K A~~~
Moder- Undiffer-
Well ate Poor entiated
Bronchogenic 38
+ 13
Stomach - 15
+ 6
Large bowel - 24
+ 5
in Bone
Bronchogenic - 43
+ 8
Stomach - 16
+ 5
Large bowel - 24
+ 5
40 < 0 005
100
50 -L< 0-0
200 f
45 }L <0*05
80 f
50
45
50
40
45
40
the tumour cell and the concentration of
ICT and CEA.
Differentiation wasnegatively correlated
with median ICT and positively with
median CEA concentration.
Bronchogenic
No. patients
Median ICT (pg/ml)
Median CEA (ng/ml)
Stomach
No. patients
Median ICT (pg/ml)
Median CEA (ng/ml)
10
30
12
8
40
9
6
20
15
8 22
105** 95**
3** 3**
11
100**
3**
Large bowel
No. patients 6 9 4
MedianICT (pg/ml) 35 170* 100**
MedianCEA (ng/ml) 14 11* 5**
*P<0 05, **P<0-01, compared to the well
differentiated subgroup in lung and large-bowel
cancer and to the moderate differentiated subgroup
in gastric cancer.
In Fig. 2 the incidences of increased
ICT and/or CEA concentrations are pre-
sented. In all groups only 25% of patients
demonstrated no increased values of
t-)
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Fie. 2. Incildence of increase(1 CEA and/or ICT (+) or normal (-) concentration in 79 patients with
bronchogenic, stomach an(l large-bowel cancer.
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Fic. 3. Acttiarial survival ofnormocalcitoninaemic (I) ancl hypercalcitoninaemic cancer patients (II).
either tumour marker. In large-bowel
carcinoma ICT is as often increased as is
CEA, and concordant elevations are found
in only 25% of all cases. In carcinoma of
the stomach and lung we found over-
lapping increases of both markers in 40
and 45%0 respectively. In these two
tumour groups, cases that were CEA+/
ICT- proved to be relatively rare (1200
and 7%0 respectively).
By contrast CEA-/ICT+ cases were
found in all groups, with an incidence of
25%0.
The higher incidence of increased ICT
than in the data of Table I could be
explained by the smaller number of
patients, as only the data of those 79
patients in whom both tumour markers
were measured, are presented in Fig. 2.
Fig. 3 shows the actuarial survival
curves for hypercalcitoninaemic and nor-
mocalcitoninaemic patients. The mean
survival of patients with a normal serum
ICT concentration is significantly longer
(log rank test).
DISCUSSION
A survey of the literature made 2 years
ago indicated that the frequency ofhyper-
CD
0
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calcitoninaemia in patients with a car-
cinoma was :30%0 (Mtulder & Hackeng,
1 978).
In this series of 1:305 unselected car-
cinoma patients with normal renal func-
tion and normal blood calcium levels,
4000 had hypercalcitonaemia.
In patients with a carcinoma of the
lung, stomach and large bowel, the inci-
dence was 40, 39 and 37 0, respectively.
All 9 patients with a hepatoma were
highly HYCAL. Adachi & Abe (1976)
found increased ICT in 11/13 patients with
hepatoma, so ICT should be considered
an important "tumour marker" in patients
with hepatoma. It was remarkable that
none of the 7 patients with a carcinoma of
the breast had increased ICT levels,
although all had metastases. This is in
contrast to the results of Coombes et at.
(1974), who found increased serum ICT
concentrations in all of 8 patients investi-
gated with breast cancer. Later Coombes
et al. (1975) showed that 23/28 patients
with this type of tumour were HYCAL.
The reason for this discrepancy is unclear.
Possible explanations could be a lower
degree of differentiation, in combination
with a higher incidence of liver meta-
stases.
Alternatively, the divergent results in
the study by Coombes and his colleagues
could be ascribed to a different ICT assay.
Our finding ofarelationship between the
change of serum ICT concentrations and
the change in tumour voume indicates
that serum ICT could be a useful treat-
ment marker (Vaitukaitis, 1976). Regres-
sion of the tumour was accompanied by a
decrease of serum ICT, and vice versa,
though an exceptional discordant course
of ICT was fouind in either clinical de-
velopment.
In lutng, stomach and large-bowel can-
cer, serum ICT was significantly higher
when metastases in the liver had de-
veloped. The finding of Coombes et al.
(1974) and Milhaud et al. (1976) that
patients with bone metastases were es-
pecially prone to HYCAL was not con-
firmed. A negative correlation between
54
serum ICT and tumour differentiation has
been shown.
Thus poorly differentiated tumours had
more frequent ectopic ICT secretion,
independent oforgan oforigin or cell type.
We have confirmed the results of other
authors that the incidence of ectopic ICT
secretion is related to histological type
(McKenzie et al., 1977; Silva et al., 1976;
Tashjian et al., 1976). The undifferentiated
type and the oat-cell have higher serum
ICT concentrations than squamous-cell
carcinomas and adenocarcinomas of the
lung. However, our findings in stomach
and colon carcinomas support the hypo-
thesis that this correlation is not primarily
dependent on cell type, but more probably
the consequence of the relationship be-
tween serum ICT andthe degreeoftumour-
cell differentiation, as demonstrated in
Table IV.
As opposed to ICT, CEA is secreted by
more differentiated tumours (Luporinin
et al., 1977) so that additional information
can be obtained when CEA and ICT are
both measured.
In our results, at least one of the two
markers was found increased in 700% of
unselected patients with a carcinoma.
Furthermore the level of serum ICT
probably has prognostic significance, as
the patients with increased values tended
to live shorter.
In conclusion, ICT can be considered
as a useful tumour marker, as 40o of
unselected patients had increased serum
concentrations, and changes in tumour
volume and ICT level proved to be related.
This finding applies not only to patients
with a bronchogenic carcinoma, as Wil-
liams (1976) predicted. However, in non-
malignant chronic disease 20% of patients
have a raised CEA, and 250% a raised
calcitonin (Mulder et al., 1980).
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